An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis

An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis

The objective of this study is to assess safety and efficacy of long-term use of AL-4943A (Olopatadine Hydrochloride Ophthalmic Solution, 0.2%) in patients with allergic conjunctivitis.

Inclusion Criteria:

• Subjects must provide written consent.
• Subjects must have a diagnosis of allergic conjunctivitis.
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Itching and/or hyperemia associated with diseases other than allergic conjunctivitis.
• Retinal detachment, diabetic retinopathy, or any progressive disease in posterior segment of the eye.
• Known history of ocular infection.
• Contact lens wear during study.
• Pregnant, nursing.
• Participation in another clinical study within 30 days of Informed Consent.
• Other protocol-defined exclusion criteria may apply.